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Summary.-Leucocytes from normal individuals and from patients with acute
myeloid leukaemia (AML) in remission receiving active immunotherapy with allo-
geneic AML blasts (AML-I) were cultured for 6 days with AML-I blasts, Burkitt's
lymphoma cells (BL) or lymphoblastoid cells (LCL). The leucocytes were then
tested for cell-mediated cytotoxicity (CMC) against 51Cr-labelled AML-I, BL or
LCL target cells. There was no substantial difference in the CMC of leucocytes
from patients and normals cultured without stimulation, and tested against AML-I,
BL or LCL targets. Patients' leucocytes stimulated in vitro with AML-I had a
greater frequency ofpositive CMC responses against AML-I, BLandLCLthan normal
individuals. The results suggest that co-cultivation of leucocytes with AML-I
blasts reactivates memory cytotoxic leucocytes in AML patients receiving immuno-
therapy and that this test may be useful in measuring the effectiveness of immuno-
therapy.
WE ARE treating a number of acute
myeloid leukaemia (AML) patients during
remission with active immunotherapy
(see Freeman et al., 1973) and without
maintenance chemotherapy. The treat-
ment protocol is based on immunotherapy
trials carried out at the Royal Marsden
and St Bartholomew's Hospitals (Powles
et al., 1973) and entails the weekly injec-
tion of x-irradiated allogeneic (donor)
AML blasts subcutaneously into 3 of the
patient's limbs and BCG into the fourth.
By analogy with animal leukaemias
(Mathe, Pouillart and Lapeyraque, 1969;
Amieland Berardet, 1970), theaim ofactive
immunotherapy is to stimulate immunity
to antigens on the donor leukaemic blasts
in the hope that such antigens may cross-
react with putative tumour-associated
rejection antigens on the surface of the
recipient's own (autochthonous) leukae-
mic blasts.
If immunotherapy is to become an
acceptable form of treatment in AML and
cancer in general, objective measurement
of its effects are necessary. Some efforts
have already been made to assess res-
ponses to immunotherapy. Thus, follow-
ing autoimmunization of patients with
their own leukaemic blasts the intensity
of leucocyte transformation by auto-
chthonous AML blasts increases (Powles
et al., 1971, Gutterman et al., 1973), though
to what extent this may be due to the
cessation of chemotherapy needs further
investigation. Active immunotherapy
with allogeneic AML blasts leads to the
appearance of antibody with anti-HL-A
specificity in some of the patients' sera
(Harris, Wentzel and Freeman, 1975;
Hersey et al., 1973; Klouda et al., 1975)
though no conclusive evidence has been
presented showing that immunotherapy
leads to the formation of antibody to
autochthonous AML blasts (see review by
Harris, 1973).
To our knowledge, no evidence has
been presented showing that leucocytes
from patients treated by active immuno-
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capable of killing either allogeneic (donor)
or autochthonous AML blasts. There-
fore, using an in vitro assay we have
sought to discover whether cell-mediated
cytotoxicity (CMC) to donor cells results
from active immunotherapy. Since CMC
assays using freshly obtained peripheral
leucocytes usually require relatively large
leucocyte to target cell ratios, we first
stimulated the leucocytes from immuno-
therapy patients and normal controls,
with AML-immunotherapy (AML-I)
blasts in vitro in the hope of expanding
the population of cytotoxic leucocytes
(CTL) and then tested them against the
same AML-J blasts and other cell lines as
targets in the CMC assay.
MATERIALS AND METHODS
Patients and controls.-The patients
studied had all beentreated with cytosine
arabinoside (Ara-C) and daunorubicin induc-
tion chemotherapy. When the patients were
judged to be in full remission by bone marrow
examination(lessthan50 blasts)theyreceived
a final course of Ara-C and daunorubicin and
commenced immunotherapy one week later.
Controls were normal laboratory personnel.
Immunotherapy.-All patients described
had received maintenance immunotherapy
consisting of weekly injections of 109 viable,
washed, x-irradiated (101 rad) allogeneic
blasts delivered intradermally/subcutan-
eously into 3 limbs, and a saline suspension
of BCG (Glaxo Laboratories, Greenford),
containing approximately 106 live organisms
delivered by 20 needle Heaf gun fired twice
into the fourth limb (Freeman et al., 1973).
Leukaeemic blasts.-Leukaemic blasts were
obtained before treatment by aspiration of
venous blood either into heparinized bottles
or, where clinically indicated, by leucophore-
sis using an NCI-IBM continuous-flowr
blood cell separator. In the case of the
leucophoresed patients, erythrocytes and
plasma were returned to the patient and the
buffy coat consisting mainly of leucocytes
was collected in a sterile blood bottle. Where
whole venous blood was aspirated into
heparin, erythrocytes were sedimented with
6% w/v dextran 110 (Fisons, Loughborough)
at 37°C. Leucocytes obtained by leuco-
phoresis or dextran sedimentation were
diluted in TC 199 buffered with sodium bi-
carbonate or HEPES (Gibco Bio-Cult,
Glasgow) containing dimethylsulphoxide
(DMSO) at 4°C to give a final suspension
medium containing 10% autologous plasma,
10% DMSO and 80% TC 199. The cells
were dispensed in 2 ml volumes containing
107-2 X 107 cells for in vitro studies, and
109 for immunotherapy, into 5 ml glass
ampoules, which were then sealed and cooled
to 4°C. The ampoules were frozen at the
rate of -1C/min to -150°C in a controlled-
rate freezer (G. V. Planer, Ltd, Middlesex,
UK) and then stored at-120°C in the vapour
phase of a liquid nitrogen storage vessel
(Union Carbide, LR-320, Darlington, UK).
Cell lines.-A cell line derived from
Burkitt's lymphoma BL (Raji) (see Klein,
1973), wasmaintained insuspension culture in
Eagle's medium (S-MEM, Gibco Bio-Cult,
Glasgow) containing 10% foetal calf serum
(FCS, Wellcome Laboratories, Kent) inFalcon
3013 culture flasks (Falcon Plastics, Oxnard,
Calif. USA) and sub-cultured twice weekly.
A normal lymphoblastoid cell line LCL
(MICH) was obtained from G. D. Searle
(High Wycombe, UK) and cultured in
RPMI-1640 containing 10% FCS.
Preparation of leucocytes.-Venous blood
was obtained simultaneously from remission
AML patients andnormal healthycontrolsand
anticoagulated by defibrination with glass
beads. A lymphocyte-rich leucocyte fraction
was obtained by layering 8 ml of blood
diluted 1: 3 with saline over 3 ml of a mixture
of 90% Ficoll (Pharmacia, Uppsala, Sweden)
and 330% Triosil (Nyegaard & Co., Oslo,
Norway) in straight-sided flat-bottomed glass
tubes (100 x 14 mm) followed by a centri-
fugation at 4°C for 40 min at 400 g (Boyum,
1968). The cells attheinterface oftheplasma
and Ficoll were removed and washed twice in
TC 199/HEPES containing 10% FCS, after
which they were resuspended in RPMI-1640
containing 1000 heat-inactivated human AB
serum.
Mixed cell cultures.-Mixed cultures (4 ml)
of patients' or normal leucocytes with AML
immunotherapy blasts or with cell lines were
initiated in screw-top glass culture tubes
(16 x 120 mm, Flow Laboratories, Scot-
land). The stimulating cells (AML-I or cell
lines) were first given a dose of 104 rad
x-irradiation from a 137Cs source and cultured
with leucocytes (2 x 106/ml) at a ratio of
one stimulating cell to 10 responding eells.
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After 6 days at 37°C, replicate cultures of
each leucocyte and stimulating cell combina-
tion were pooled, washed once in TC 199
HEPES and leucocytes adjusted to 1-2x
106/ml.
Cell-mediated cytotoxicity (CMC).-Target
cells for the CMC assay were the same cells
used to stimulate in the sensitization phase
ofthe test. They were labelled for 1 h with
01 ml of Na251CrO4 (sp. act. 1 mCi/ml
Radiochemical Centre, Amersham) per 5 x
106 cells in TC 199/HEPES then washed in a
tenfold volume of the same culture medium,
re-incubated in 10 vol ofthis medium for 1 h,
further washed and adjusted to 105 cells/ml.
For CMC tests, cultured normal or patient
leucocytes (0 1 ml) were added to each well in
sterile styrene plates with 96 flat-bottomed
wells (Cooke Microtitre, M29 ART, Dynatech
Laboratories, Billinghurst) so that each
target cell was exposed to each leucocyte
culture combination, each test being repro-
duced in quadruplicate wells. The plates
were centrifuged at 60 g for 2 min, covered
and incubated at 37°C for 4 h. They were
then cooled at 4°C, briefly re-spun at 60 g
and 01 ml of supernatant medium removed
from each well and placed in plastic tubes.
The supernatant was counted for 51Cr in a
Wallac DECEM GTL 300-500 Gamma
scintillation counter. Percentage CMC was
calculated from (E - S/T -S) x 100 where
E = 51Cr release inthepresence ofleucocytes,
S = spontaneous 51Cr release by target cells
alone and T = total release from target cells
alone freeze-thawed x 3. Specific CMC was
calculated by subtracting the percentage CMC
on target cells in the presence ofunstimulated
leucocytes from the percentage CMC in the
presence of stimulated leucocytes. The sig-
nificance of 51Cr release from the target cells
was calculated by Student's t tests
comparing (1) 51Cr release by unstimulated
leucocytes with 51Cr release by target cells
alone and (2) 51Cr release with stimulated
compared with unstimulated leucocytes.
RESULTS
The results of 2 representative experi-
ments comparing leucocytes from patients
with normal controls are shown in Table I.
In both experiments, neither unstimu-
lated normal nor patients' leucocytes
cultured in vitro for 6 days showed signifi-
cant cytotoxicity to any (AML-J, BL or
LCL) of the target cells. In contrast,
leucocytes from the patients receiving
AML-I blasts as part of their treatment
and re-stimulated in vitro with AML-J
blasts showed strong specific cytotoxicity
to AML-J blasts and to BL and LCL cells,
whereas normal leucocytes cultured with
AML-I blasts were not cytotoxic. Stimu-
lation of normal and patient leucocytes
TABLE I.-Cell Mediated Cytotoxicity of Unstimulated and Stimulated Leucocytes from
2 Normal and 2 AML Patients
Stimulation
Percentage cytotoxicity witht
-' ~~~A
Experiment Leucocytes from Immunotherapy in vitro AML-I Raji MICH
1. Normal (IS) 1-97 2-12 0
Patient (BH) AML-I -0-65 0-41 -2-0
Normal AML-I -0-66 -2-53 -4-6
Patient AML-I AML-I 52-35*** 4-65 15-2**
Normal Raji -3-87 -2-19 -2-3
Patient AML-I Raji -1-75 -2-87 2-4
Normal - MICH -4 07 -2-53 -1-45
Patient AML-I MICH -2-45 -9-41 -1-0
2. Normal (CP) -1-07 -4-72 -2-58
Patient (AH) AML-I -2-49 -5 49 -4-89
Normal AML-I 0-62 0-32 -2-3
Patient AML-I AML-I 8-04*** 12-05*** 3-63
Normal Raji 3-97 50-12*** 40.5***
Patient AML-I Raji 0-51 7-76*** 6-81
Normal MICH -0-61 9-56*** 25-0***
Patient AML-I MICH 2-29 15-14*** 13-09***
**P<0-01. ***P<0.005.
t Cytotoxicity with unstimulated leucocytes, specific cytotoxicity with stimulated leucocytes (see
Materials and Methods).
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in vitro with Raji (BL) or MICH (LOL)
cells produced different effects depicted in
Table I. No cytotoxicity occurred in
Experiment 1 either to Raji or MICH but
cytotoxicity did develop in normal and
AML patient leucocytes in Experiment 2.
This cytotoxicity was cross-reactive since
Raji-stimulated leucocytes were cyto-
toxic to MICH target cells (Experiment 2,
normal) and MICH-stimulated' leucocytes
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were cytotoxic to Raji targets (Experi-
ment 2, normal and patient). However,
no cytotoxicity was observed whenRaji-
or MICH-stimulated leucocytes (normal
orAML) weretested on AML target cells.
TheCMCvalues inthese 2 experiments,
and a series of 7 similar experiments
in which patients receiving immuno-
therapy were compared with normal
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FIG.-Results of CMC tests of unstimulated (A) and AML-I blast (B), BL (Raji) (C), or LCL (MICH)
(D), stimulated normal (N) or leukaemic (L) leucocytes. Each leucocyte preparation was tested
against AML-I, Raji and MICH target cells. The points indicate the individual CMC values
of each test, in Fig. (A) showing the % cytotoxicity and Fig. (B-D) the % specific cytotoxicity (see
Methods). Two different stimulatory AML blasts were used, depicted in Fig. (B) (O, 0).
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TABLE II.-Summary of Cell-mediated Cytotoxic Tests of AML Immunotherapy Patients
and Controls
Leacocytes from
Normals
Patients
Normals
Patients
Normals
Patients
Normals
Patients
Immunotherapy
AML-I
AML-I
AML-I
AML-I
No. ofpositive tests/No. tested (%+ve) VS:
Stimulation I 4 l
in vitro AML-I Raji MICH
- 1/8/(12.5)- 1/9(11) 2/8(25)
0/8(0) 3/9(33) 3/8(37)
AML-I 1/8(12.5) 4/9(44) 1/8(12-5)
AML-I 6/8(75) 6/9(66) 3/8(37)
Raji 4/8(50) 3/9(33) 3/8(37)
Raji 3/8(37) 3/8(37) 3/7(42)
MICH 2/5(40) 4/6(66) 3/6(50)
MICH 2/5(40) 4/5(80) 3/5(60)
in Table I, unstimulated and stimulated
leucocytes were tested against 3 target
cells (AML-J, Raji, MICH), the results
for each test having been plotted in the
appropriate column of the Figure. The
variation in CMC with unstimulated
patient and normal leucocytes is seen to
be greater when tested against Raji and
MICH targets compared with AML-1
targets (Fig. A). However, the specific
CMC of patient leucocytes stimulated by
AML-I blasts is considerably enhanced
compared with normal leucocytes on
AML-targets but not on Raji, and less so
on MICH targets (Fig. B). The result of
stimulating leucocytes with Raji or MICH
cells (Fig. C and D) did not particularly
enhance the CMC by patient compared
with normal leucocytes, though both
groups showed greater CMC compared
with unstimulated leucocytes (Fig. A),
particularly those cultures stimulated with
MICH cells and tested against MICH and
Raji targets (Fig. D).
The results shown in Table II com-
pare the frequency ofsignificantly positive
cytotoxic tests in normals and patients
taken from the values depicted in the
Figure. The frequency of positive tests
using unstimulated normal or patient
leucocytes did not greatly differ whereas
the frequency of positive tests in which
AML-I blast-stimulated leucocytes were
cytotoxic to AML-J targets was much
higher in patients compared with normals
and was higher when these same patients'
leucocytes were tested against Raji and
MICH cells. In contrast, the frequency
10
of positive cytotoxic reactions using Raji-
and MICH-stimulated leucocytes against
all 3 target cell types was not markedly
different when patients were compared
with normals. The HL-A phenotypes of
normal and AML patients leucocytes and
the stimulating AML blasts were not
matched in these experiments, thus differ-
ences were present in all cases with
respect to the HL-A major histocompati-
bility complex (Thorsby, 1974).
DISCUSSION
The CMC test described here is based
on observations originally made in the
mouse (Haiyry and Defendi, 1970) and
confirmed in man (Lightbody and Bach,
1972; Solliday and Bach, 1972) that
stimulation of leucocytes in vitro with
allogeneic cells induces the differentiation
of killer cells capable of destroying target
cells possessing the same alloantigens as
the stimulating cells. The results pre-
sented in this study show that unstimula-
ted normal and AML patients' leucocytes
and normal leucocytes stimulated with
allogeneic AML-J blasts in vitro usually
do not possess the capacity to kill AML-I
blasts in vitro. Conversely, leucocytes
from patients receiving allogeneic AML-I
blasts as their immunotherapy and re-
stimulated in vitro with these cells exhi-
bited significant specific cytotoxicity to
the AML-I blast targets in three-quarters
of the patients tested. To test the
specificity, we also performed parallel
cross tests with leucocytes from patients
and normal subjects stimulated with cell
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lines and we found that the responses to
the cell lines were similar in the normals
and patients. Since all AML patients in
the Manchester trial have so far received
immunotherapy during remission, we
have not had an opportunity to study
unimmunized AML controls. However,
it is likely that the greater frequency of
positive cytotoxic tests in the AML
patients against AML-J targets, and the
higher percentage cytotoxicity values for
individual AML patients compared with
normal controls tested simultaneously,
is a reflection of the previous sensitization
of these patients by immunotherapy.
Moreover, the similar frequency of posi-
tive responses to the cell lines by the
controls and patients suggests that both
groups are responding in a similar way to
cells to which neither has previously been
immunized. A more accurate assess-
ment of the effect of immunotherapy on
the CMC response will be possible follow-
ing a comparison of patients wvith a
normal HL-A-identical sibling and be-
tween AML patients receiving main-
tenance immunotherapy and those in the
new Manchester trial who are not.
The antigens responsible for reactiva-
tion of CMC in the AML patients studied
here are not known. Leucocyte stimula-
tion in allogeneic normal mixed leucocyte
cultures (MLC) depends upon differences
in antigens controlled by the major
histocompatibility complex, the so-called
leucocyte defined (LD) antigens (Amos
and Bach, 1968; Yunis and Amis, 1971;
Eijsvoogel et al., 1973). Leucocyte acti-
vation by LD antigens seems to be essen-
tial for the development of cytotoxicity
to serologically defined (SD) HL-A anti-
gens on the target cells (Eijsvoogel et al.,
1973). Whilst AML-I blasts from differ-
ent patients often stimulate normal leuco-
cytes in vitro (Taylor et al., unpublished),
it is not clear why such activated normal
leucocytes in our experiments generally
fail to exhibit cytotoxicity to AML-J
blasts as targets since HL-A SD antigens
are known to be present on AML blasts
(Harris et al., 1975). It is possible that
AML-J blasts are relatively refractory to
killing by cytotoxic leucocytes developed
after in vitro stimulation while the strong
cytotoxicity of leucocytes from patients
stimulated both in vivo byimmunotherapy
and in vitro with the same AML-1 blasts
indicate a quantitative or qualitative
difference in the response compared with
normal leucocytes. Recently, Cerottini
et al. (1974) have demonstrated that
spleen cells from mice preimmunized in
vivo with allogeneic tumour cells and
cultured in vitro with the same tumour
cells produced a much higher level of
cytotoxicity compared with non-immune
spleen cells cultured in the same way.
These workers (MacDonald et al., 1974)
suggest that cytotoxic leucocytes differ-
entiate to become long-lived memory
cells which gradually lose their cytotoxi-
city but which reappear upon re-exposure
to alloantigen. The difference between
normal and AML remission leucocytes
could be explained in a similar way by
regarding the responding cells in the
AML-J-stimulated patient leucocyte cul-
tures as memory cytotoxic leucocytes
which are unable to mediate CMC without
reactivation in vitro.
The cross-reactive cytotoxicity of
normal and patient leucocytes on Raji
and MICH cells suggests the participation
of common stimulating/target antigens.
Both cell lines are positive for Epstein-
Barr virus nuclear antigen (Taylor, un-
published observations) which could be
responsible for determining common cell-
surface antigens. The fact that AML-J-
stimulated patient leucocytes were also
cytotoxic to both cell lines in some tests
whilst cell line-stimulated normal and
patient leucocytes were cytotoxic to
AML-J blasts, suggests the participation
of common target HL-A SD antigens in
these tests, since AML-J blasts are devoid
of the EB virus genome (Taylor, un-
published observations).
The requirements for the successful
active immunotherapy of remission AML
patients should be the effectiveness of
the allogeneic AML-J blasts as primary
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immunogens and continuous recruitment
thereafter of cytotoxic leucocytes from a
pool of memory leucocytes. To this end,
these studies indicate that immuno-
therapy is achieving this aim, at least in
terms of immunity to allogeneic immuno-
therapy blasts. However, a more rational
basis for the selection of AML-I blasts
should be the object of further study
since some blasts are known to be non-
stimulatory. WhetherimmunitytoAML-I
blasts is cross-reactive with autoch-
thonous AML blasts is more open to
doubt in view of our failure, so far, to
detect cross-reactivity in several experi-
ments with different patients.
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